Bavarian Nordic still hopes to find financing for Covid-19 vaccine
In spite of positive preclinical data, Bavarian Nordic maintains that the firm itself will not finance further studies after the first phase I/II study. The company remains optimistic, however, about the prospects of finding capital for the vaccine from external sources.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
While Bavarian Nordic's vaccine candidate against Covid-19 will soon enter into the first in-human phase I/II study, the Danish vaccine company is on the lookout for a partner to finance its further development and the process of taking the Covid-19 vaccine to market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers
